CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Revenue (Most Recent Fiscal Year) | $0.42M |
Net Income (Most Recent Fiscal Year) | $-22.56M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.72 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -6083.57% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -448.19% |
Return on Assets (Trailing 12 Months) | -151.29% |
Current Ratio (Most Recent Fiscal Quarter) | 0.91 |
Quick Ratio (Most Recent Fiscal Quarter) | 0.91 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.72 |
Earnings per Share (Most Recent Fiscal Quarter) | $-6.23 |
Earnings per Share (Most Recent Fiscal Year) | $-26.75 |
Diluted Earnings per Share (Trailing 12 Months) | $-27.22 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 0.84M |
Free Float | 0.77M |
Market Capitalization | $1.65M |
Average Volume (Last 20 Days) | 0.04M |
Beta (Past 60 Months) | 0.56 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 8.47% |
Percentage Held By Institutions (Latest 13F Reports) | 23.58% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |